

CLAIMS

1. – 105. (cancelled)

106. (currently amended) A method of screening a patient perioperatively to determine a risk for complications during a surgical procedure associated with known genetic variations comprising:

- a) obtaining a sample from a perioperative subject, said perioperative subject being a patient scheduled for a surgical procedure that has not yet completed said surgical procedure; and
- b) subjecting said sample to an assay for detecting two or more nucleic acid genetic markers in two or more genes associated with two or more conditions to generate a genomic profile; and
- c) selecting a perioperative course of action based on information from said genomic profile, wherein said subjecting step occurs after said patient is scheduled for surgery but before completion of said surgical procedure, thereby determining a risk for complications during said surgical procedure[.]; and
- d) performing said surgical procedure wherein said perioperative course of action is used by at least one of the group consisting of an anesthesiologist, a nurse, and a surgeon.

107. (previously presented) The method of Claim 106, wherein said surgical procedure is the first surgical procedure for said subject.

108. (previously presented) The method of Claim 106, wherein previous said surgical procedures on said patient have been with one or more complications.

109. (previously presented) The method of Claim 106, wherein said course of action comprises administration of anesthesia during a surgical procedure.

110. (previously presented) The method of Claim 109, wherein said anesthesia is

general anesthesia.

111. (previously presented) The method of Claim 110, wherein said general anesthesia is inhalational anesthesia.

112. (previously presented) The method of Claim 110, wherein said general anesthesia is intravenous anesthesia.

113. (previously presented) The method of Claim 109, wherein said anesthesia is regional anesthesia.

114. (previously presented) The method of Claim 113, wherein said regional anesthesia is spinal or epidural anesthesia.

115. (previously presented) The method of Claim 106, wherein said surgical procedure is non-invasive surgery.

116. (previously presented) The method of Claim 106, wherein said surgical procedure is invasive surgery.

117. (previously presented) The method of Claim 106, wherein said course of action comprises administration of anesthesia during a medical procedure.

118. (previously presented) The method of Claim 106, wherein said genomic profile comprises information pertaining to a pharmacodynamic risk.

119. (previously presented) The method of Claim 106, wherein said genomic profile comprises information pertaining to a pharmacokinetic risk.

120. (previously presented) The method of Claim 106, wherein said genomic profile comprises a presymptomatic diagnosis.

121. (previously presented) The method of Claim 106, wherein said genomic profile comprises information pertaining to differential diagnosis of co-existing diseases.

122. (previously presented) The method of Claim 106, wherein said two or more nucleic acid genetic markers comprise mutations in two or more genes, said genes selected from the group consisting of *BChE*, *CYP2D6*, *MTHFR*, *MTR*, *CBS*, *F2*, *F5*, *RYR1*, *CACNA1S*, and *CPT2*.

123. (previously presented) The method of Claim 122, wherein said two or more nucleic acid genetic markers comprise 5 or more mutations in two or more genes.

124. (previously presented) The method of Claim 122, where in said two or more nucleic acid genetic markers comprise 10 or more mutations in two or more genes.

125. (currently amended) The method of Claim 106, wherein said genomic profile consists of alleles in genes encoding BChE, CYP2D6, MTHFR, MTR, CBS, F2, F5, RYR1, CACNA1S, and CPT2, and $TNF\alpha$ ~~and~~ $TNF\beta$.

126. (cancelled)

127. (previously presented) A method for selecting conditions for a surgical procedure by screening a patient perioperatively to determine a risk for complications during a surgical procedure associated with known genetic variations comprising:

- a) providing a sample from a perioperative subject, said perioperative subject being a patient scheduled for a surgical procedure that has not yet completed said surgical procedure;
- b) subjecting said sample to an assay for detecting two or more nucleic acid genetic markers in two or more genes known to be associated with two or more perioperative phenotypes to generate a genomic profile;
- c) selecting a surgical procedure treatment course of action based

- on information from said genomic profile; and
- d) subjecting said subject to a surgical procedure.

128. (previously presented) The method of Claim 127, wherein said genetic markers are associated with a pharmacological response.

129. (previously presented) The method of Claim 128, wherein said pharmacological response is to an anesthetic.

130. (previously presented) The method of Claim 128, wherein said pharmacological response is to drugs used in anesthetic practice.

131. (previously presented) The method of Claim 127, wherein said two or more nucleic acid genetic markers comprises a mutation in two or more genes associated with two or more conditions, said genes selected from the group consisting of *BChE*, *CYP2D6*, *MTHFR*, *MS*, *CBS*, *F2*, *F5*, *RYR1*, *CACNA1S*, and *CPT 2*.

132. (previously presented) The method of claim 131, wherein said two or more nucleic acid genetic markers comprises 5 or more mutations in two or more genes.

133. (previously presented) The method of claim 131, wherein said two or more nucleic acid genetic markers comprises 10 or more mutations in two or more genes.

134. (currently amended) The method of Claim 127, wherein said genomic profile consists of alleles in genes encoding BChE, CYP2D6, MTHFR, MTR, CBS, F2, F5, RYR1, CACNA1S, and CPT2, and $\text{TNF}\alpha$ ~~and~~ $\text{TNF}\beta$.

135. (previously presented) A method of screening a patient perioperatively to determine a risk for complications during a surgical procedure from known genetic variations comprising:

- a) obtaining a sample from a perioperative subject, said perioperative

subject being a patient scheduled for a surgical procedure that has not yet completed said surgical procedure; and

- b) subjecting said sample to an assay for detecting genetic markers in genes clinically associated with conditions consisting of butyrylcholinesterase deficiency, impaired debrisoquine metabolism, sepsis, thrombosis, and malignant hyperthermia to generate a genomic profile;
- c) directing a physician to a perioperative treatment course of action based on information from said genomic profile for determining a risk for complications during a surgical procedure; and
- d) subjecting said subject to a surgical procedure.

136. (previously presented) The method of Claim 135, wherein said physician is an anesthesiologist.

137. (previously presented) The method of Claim 135, wherein said course of action comprises administration of anesthesia during a surgical procedure.

138. (previously presented) The method of Claim 135, wherein said physician is a surgeon.

139. (previously presented) The method of Claim 135, wherein said surgical procedure is non-invasive surgery.

140. (previously presented) The method of Claim 135, wherein said surgical procedure is invasive surgery.

141. (previously presented) The method of Claim 135, wherein the said two or more nucleic acid genetic markers comprises 5 or more mutations in two or more genes.

142. (previously presented) The method of Claim 135, wherein the said two or more nucleic acid genetic markers comprises 10 or more mutations in two or more genes.

143. (currently amended) A method of screening a patient perioperatively to determine a risk for complications during a surgical procedure from known genetic variations comprising:

- a) obtaining a sample from a perioperative subject, said perioperative subject being a patient scheduled for a surgical procedure that has not yet completed said surgical procedure; ~~and~~
- b) subjecting said sample to an assay for detecting two or more nucleic acid genetic markers in two or more genes clinically associated with butyrylcholinesterase deficiency and impaired debrisoquine metabolism to generate a genomic profile;
- c) directing a physician to a perioperative treatment course of action based on information from said genomic profile for determining a risk for complications during a surgical procedure; and
- d) subjecting said subject to a surgical procedure.

144. (currently amended) A method for selecting an appropriate anesthesia treatment during surgery, comprising:

- a) providing a sample from a perioperative subject, said perioperative subject being a patient scheduled for a surgical procedure that has not yet completed said surgical procedure; ~~and~~
- b) subjecting said sample to an assay that detects a first marker in a first gene and a second marker in a second gene to generate assay results, wherein said markers are known to be associated with adverse responses to anesthesia treatment; and
- c) subjecting said subject to a surgical procedure, wherein said assay results are consulted by a physician in selecting an appropriate anesthesia treatment for said subject based on information from said assay results.

145. (previously presented) The method of Claim 144, wherein said physician is an anesthesiologist.

146. (previously presented) The method of Claim 144, wherein said selecting comprises selection of dosages of anesthesia.

147. (previously presented) The method of Claim 144, wherein said selecting comprises selection of anesthesia compounds.

148. (previously presented) The method of Claim 144, wherein said selecting comprises selection of monitoring procedures.

149. (currently amended) A method for providing a perioperative course of action to a clinician based on a patient's risk for complications during and after a surgical procedure associated with known genetic variations, comprising:

- a) obtaining consent from a patient to obtain and assay a sample from a perioperative subject for genetic variations, said patient being a patient scheduled for a surgical procedure that has not yet completed said surgical procedure;
- b) obtaining said sample from said patient;
- c) forwarding said sample to a clinical laboratory;
- d) isolating DNA from said sample in said clinical laboratory;
- e) subjecting said DNA to an assay in said clinical laboratory for detecting two or more nucleic acid genetic markers in two or more genes associated with two or more conditions to generate a genomic profile wherein said subjecting step occurs after said patient is scheduled for surgery but before completion of said surgical procedure;
- f) forwarding the results of said genomic profile to said clinician;
- g) directing said clinician to a perioperative course of action for said patient based on said risk for complications during and after said surgical procedure based on information from said genomic profile;
- h) subjecting said patient to a surgical procedure based on said perioperative course action;
- i) distributing said results of said patient's said genomic profile according to said patient's preference wherein said distributing is selected from the group consisting of

destroying said results, saving said results for future access by said patient, saving said results for future access by said clinician, and donating said results for research; and j[[.]] distributing said patient's said sample according to said patient's preference wherein said distributing is selected from the group consisting of destroying said sample, saving said sample for future access, and donating said sample for research.

150. (previously presented) The method of Claim 149, wherein said directing said clinician to said perioperative course of action comprises a computer program comprising instructions which direct a processor to analyze said results of said genomic profile.

151. (previously presented) The method of Claim 150, wherein said instructions translate said results into information of predictive value for a clinician.

152. (previously presented) The method of Claim 150, wherein said instructions translate said results into a risk assessment for treatment options.

153. (previously presented) The method of Claim 150, wherein said instructions translate said result into recommendations for treatment options.

154. (previously presented) The method of Claim 150, wherein said instructions generate a report for display to a clinician.

155. (previously presented) The method of Claim 154, wherein said display is in the form of a report that can be printed.

156. (previously presented) The method of Claim 154, wherein said display is in the form of a report on a computer monitor.

157. (previously presented) The method of Claim 150, wherein said instructions are sufficient to receive, process and transmit said results of said genomic profile to and from said patient, a clinical laboratory and medical personnel.

158. (previously presented) The method of Claim 157, wherein said transmission of said results uses an electronic communication system.

159. (previously presented) The method of Claim 158, wherein said electronic communication system transmits said results to a distant computer system for processing.

160. (currently amended) The method of Claim 150, wherein said instructions comprise information to optimize perioperative care that, based on at least the presence of variant alleles of two or more genes associated with two or more conditions selected from the group consisting of *BChE*, *CYP2D6*, *F5*, *F2*, *CACNAIS*, *MTHFR*, *MTR*, *MTRR*, *CBS*, and *TNF α* ~~and *TNF β*~~ , directs said clinician to a specific perioperative clinical pathway for said patient.

161. (previously presented) The method of Claim 149, wherein said perioperative course of action is an anesthesia treatment course of action.

162. (previously presented) The method of Claim 161, wherein said anesthesia treatment course of action is a general anesthesia course of action.

163. (previously presented) The method of Claim 162, wherein said general anesthesia treatment course of action is an inhalational anesthesia treatment course of action.

164. (previously presented) The method of Claim 162, wherein said general anesthesia treatment course of action is an intravenous anesthesia treatment course of action.

165. (previously presented) The method of Claim 162, wherein said general anesthesia treatment course of action is a combined inhalational and intravenous anesthesia treatment course of action.

166. (previously presented) The method of Claim 161, wherein said anesthesia treatment course of action is a regional anesthesia treatment course of action.

167. (previously presented) The method of Claim 161, wherein said anesthesia treatment course of action is a combined regional and general anesthesia treatment course of action.

168. (previously presented) The method of Claim 149, wherein said perioperative treatment course of action is an anesthesia course of action during a medical procedure.

169. (previously presented) The method of Claim 149, wherein said perioperative treatment course of action comprises selection of dosages of analgesic compounds.

170. (previously presented) The method of Claim 169, wherein said selection comprises increasing the dosage of analgesic compounds metabolized by CYP2D6.

171. (previously presented) The method of Claim 169, wherein said selection comprises decreasing the dosage of analgesic compounds metabolized by CYP2D6.

172. (previously presented) The method of Claim 149, wherein said perioperative treatment course of action comprises prophylaxis for thrombosis.

173. (previously presented) The method of Claim 172, wherein said prophylaxis comprises increasing prophylaxis for thrombosis associated with variant alleles of *F5*, *F2*, *MTHFR*, *MTR*, *MTRR*, and *CBS*.

174. (previously presented) The method of Claim 172, wherein said prophylaxis comprises decreasing prophylaxis for thrombosis associated with variant alleles of *F5*, *F2*, *MTHFR*, *MTR*, *MTRR*, and *CBS*.

175. (previously presented) The method of Claim 149, wherein said perioperative course of action comprises monitoring procedures.

176. (currently amended) The method of Claim 149, wherein said perioperative ~~treatment~~ course of action comprises pre-operative phenotypic tests and consultations.

177. (previously presented) The method of Claim 149, wherein said risk of complications provides a prognosis after an anesthesia treatment course of action.

178. (previously presented) The method of Claim 149, wherein said perioperative course of action is a surgical treatment course of action.

179. (previously presented) The method of Claim 178, wherein said surgical treatment course of action is a non-invasive surgical treatment course of action.

180. (previously presented) The method of Claim 178, wherein said surgical treatment course of action is an invasive surgical treatment course of action.

181. (previously presented) The method of Claim 149, wherein said risk of complications provides a prognosis after a surgical treatment course of action.

182. (previously presented) The method of Claim 149, wherein said perioperative treatment course of action comprises a post-operative treatment course of action.

183. (previously presented) The method of Claim 149, wherein said perioperative treatment course of action directs a clinician to a specific clinical pathway of medical intervention for said patient.

184. (previously presented) The method of Claim 149, wherein said perioperative treatment course of action directs a clinician to a specific clinical pathway of anesthesia intervention for said patient.

185. (previously presented) The method of Claim 149, wherein said assay comprises structure-specific cleavage of oligonucleotide probes assay.

186. (currently amended) The method of Claim 149, wherein said subjecting said DNA to an said assay further comprises:

- i. providing a kit for generating a perioperative genomic profile for a subject, comprising:
 - a) reagents configured such that when exposed to a sample containing target nucleic acid from a perioperative subject, said subject being a patient scheduled for a surgical procedure that has not yet completed said surgical procedure, are sufficient to detect the presence or absence of variant alleles in two or more genes associated with two or more conditions selected from the group consisting of *BChE*, *CYP2D6*, *F5*, *F2*, *CACNAIS*, *MTHFR*, *MTR*, *MTRR*, *CBS*, and *TNF α* ~~and~~ *TNF β* so as to generate a genomic profile for use in selecting a perioperative course of action for said subject; and
 - b) a computer program on a computer readable medium comprising instructions which direct a processor to analyze data derived from use of said reagents[.]; and
- ii. generating said genomic profile with said kit.

187. (currently amended) The method of Claim 149, further comprising the step of encrypting said results of said genomic profile with privacy security protocols.

188. (currently amended) The method of Claim 149, further comprising the step of decoding said results of said genomic profile with privacy security protocols.

189. (currently amended) A method of screening a patient perioperatively to determine a risk for complications during a surgical procedure associated with known genetic variations comprising:

- a) obtaining a sample from a perioperative subject, said perioperative subject being a patient scheduled for a surgical procedure that has not yet completed said surgical procedure; and
- b) subjecting said sample to an assay for detecting two or more nucleic acid genetic markers in two or more genes associated with two or more conditions to generate a genomic profile, wherein said markers are selected by the criteria of analytical validity, clinical validity and clinical utility; and
- c) selecting a perioperative course of action based on information from said genomic profile, wherein said subjecting step occurs after said patient is scheduled for surgery but before completion of said surgical procedure, thereby determining a risk for complications during said surgical procedure;
- e) distributing said results of said patient's said genomic profile according to said patient's preference wherein said distributing is selected from the group consisting of destroying said results, saving said results for future access by said patient, saving said results for future access by said clinician, and donating said results for research; and
- [[e]] f) distributing said patient's said sample according to said patient's preference wherein said distributing is selected from the group consisting of destroying said sample, saving said sample for future access, and donating said sample for research.

190. (previously presented) The method of Claim 189, wherein said selecting of markers, said subjecting said sample to said assay, and said distributing of said results of said patient's said genomic profile is organized by an integrated electronic system.

191. (previously presented) The method of Claim 189, further comprising the step of selecting said genetic markers from the group consisting of genetic markers of

pharmacogenetic risk, genetic markers of co-existing symptomatic conditions, genetic markers of co-existing non-symptomatic conditions, genetic markers of outcomes of a surgical procedure, genetic markers of a patient in a specific group, genetic markers that predict postoperative outcomes, and genetic markers consisting of unique genomic identifiers.